voncento
csl behring gmbh - mänskliga koagulationsfaktorer viii, mänskliga von willebrand faktor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrands sjukdom (vwd)profylax och behandling av blödning eller kirurgisk blödning hos patienter med vwd, när desmopressin (ddavp) som ensam behandling är ineffektiva eller kontraindicerat. hemofili a (medfödd faktor viii-brist)profylax och behandling av blödning hos patienter med hemofili a.
sporimune vet. 50 mg/ml oral lösning
medartuum ab - ciklosporin - oral lösning - 50 mg/ml - ciklosporin 50 mg aktiv substans; etanol, vattenfri hjälpämne; makrogolglycerolhydroxistearat hjälpämne - hund, katt
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
sporimune vet. 50 mg/ml oral lösning
2care4 aps - ciklosporin - oral lösning - 50 mg/ml - etanol, vattenfri hjälpämne; makrogolglycerolhydroxistearat hjälpämne; ciklosporin 50 mg aktiv substans - hund, katt
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - prekursorcell lymfoblastisk leukemi-lymfom - antineoplastiska medel - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
bactrim 40 mg/ml + 8 mg/ml oral suspension
eumedica pharmaceuticals gmbh - sulfametoxazol; trimetoprim - oral suspension - 40 mg/ml + 8 mg/ml - metylparahydroxibensoat hjälpämne; propylparahydroxibensoat hjälpämne; trimetoprim 8 mg aktiv substans; sulfametoxazol 40 mg aktiv substans; sorbitol hjälpämne - sulfametoxazol och trimetoprim
bactrim 400 mg/80 mg tablett
eumedica pharmaceuticals gmbh - sulfametoxazol; trimetoprim - tablett - 400 mg/80 mg - sulfametoxazol 400 mg aktiv substans; trimetoprim 80 mg aktiv substans - sulfametoxazol och trimetoprim
bactrim forte 800 mg/160 mg tablett
eumedica pharmaceuticals gmbh - sulfametoxazol; trimetoprim - tablett - 800 mg/160 mg - sulfametoxazol 800 mg aktiv substans; trimetoprim 160 mg aktiv substans - sulfametoxazol och trimetoprim
bactrim forte 800 mg/160 mg tablett
orifarm ab - sulfametoxazol; trimetoprim - tablett - 800 mg/160 mg - trimetoprim 160 mg aktiv substans; sulfametoxazol 800 mg aktiv substans